Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com

RGX-019

RGX-019 is an investigational drug candidate. Rgenix is developing RGX-019, a monoclonal antibody that targets MerTK, for the treatment of solid tumors.  Rgenix in-licensed RGX-019 and other antibody intellectual property from Rockefeller University as part of a world-wide exclusive licensing agreement.

Rgenix identified MerTK as a novel cancer target in triple-negative breast cancer (TNBC) in collaboration with the Rockefeller University by using the company’s proprietary target discovery platform.1  MerTK is a receptor tyrosine kinase of the TAM family and is over-expressed in several human cancers.2  The MerTK pathway drives cancer progression, tumor angiogenesis, and innate immune activation2,3  Targeting MerTK affects tumor associated macrophage polarization in part by changing them from a pro-tumorigenic M2 state to an anti-tumorigenic M1 state.  Rgenix plans to initiate IND-enabling studies of RGX-019 in 2019.

Pipeline

RGX-104

RGX-104 is a novel oral small molecule immunotherapy in development for the treatment of solid tumors, including drug-resistant malignancies.

Pipeline

RGX-202

RGX-202 is an oral small molecule cancer metabolism inhibitor in development for the treatment of gastrointestinal cancer.

References:
1. Png KJ et al. Nature. 2011 Dec 14;481(7380):190-4.
2. Graham DK. Nat Rev Cancer. 2014 Dec;14(12):769-85.2.
3. Rothlin CV. Annu Rev Immunol. 2015; 33:355-91.